HeyJaredHematology Pills
Hematology Pills is a new format based on monthly discussions between Prof. Robin Foà (Rome) and Dr. Filippo Milano (Seattle).
- Indexed episodes, last 90 days
- 3
- Latest publication
- Sep 18, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 20, 2026
Latest episodes
Beyond the Storm: Preventing and Managing CAR-T Toxicities – A Dialogue Between Robin Foà, Filippo Milano and Jordan Gauthier (opens the original)
Read excerpt
In this episode, Prof. Robin Foà and Prof. Filippo Milano are joined by Dr. Jordan Gauthier, Associate Professor at the Fred Hutchinson Cancer Center and an internationally recognized expert in the management of CAR-T cell toxicities. The conversation explores how the field has evolved from acautious, reactive approach to immune-related complications toward proactive, biomarker-guided prevention—an evolution essential to extending the safe use ofCAR-T therapy beyond major academic centers. The d
Fifty Years of Hematopathology: From Morphology to AI (opens the original)
Read excerpt
In this episode, Prof. Robin Foà and Dr. Filippo Milano arejoined by Prof. Stefano Pileri, one of the world's leading hematopathologistsand a key contributor to the WHO Classification of Hematolymphoid Tumors. Inspired by his recent book, Where do we come from? What are we? Where are we going? A journey through theevolution of Pathological Anatomy over the last half century , the conversation retraces the remarkable evolution of hematopathology—from the era of purely morphological diagnosis to t
From CML to AML: Precision Medicine, Global Access, and the Future of Leukemia Care – A Dialogue Between Robin Foà, Filippo Milano and Jerald Radich (opens the original)
Read excerpt
In this episode, Prof. Robin Foà, Dr. Filippo Milano, and Dr. Jerald Radich revisit the extraordinary journey of chronic myeloid leukemia (CML), one of the greatest success stories in modern hematology and the disease that transformed precision medicine from concept to clinical reality. The discussion retraces the evolution of CML treatment, from an era when bone marrow transplantation represented the only curative option to the revolutionary introduction of tyrosine kinase inhibitors (TKIs), wh
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Not enough subject data for this period yet.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.